SK bioscience Co.,Ltd. (KRX:302440)
South Korea · Delayed Price · Currency is KRW 48,900
-450 (-0.91%)
Last updated: Sep 9, 2025, 2:48 PM KST
SK bioscience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 534,914 | 267,545 | 369,506 | 456,726 | 929,001 |
Other Revenue | - | - | - | -0 | - |
| 534,914 | 267,545 | 369,506 | 456,726 | 929,001 | |
Revenue Growth (YoY) | 44.00% | -27.59% | -19.10% | -50.84% | - |
Cost of Revenue | 490,334 | 237,466 | 227,681 | 217,443 | 358,968 |
Gross Profit | 44,581 | 30,079 | 141,824 | 239,283 | 570,033 |
Selling, General & Admin | 108,275 | 87,056 | 60,841 | 61,801 | 46,027 |
Research & Development | 65,181 | 71,353 | 85,743 | 57,960 | 47,250 |
Other Operating Expenses | 1,180 | 1,274 | 1,417 | 664.99 | 388.56 |
Operating Expenses | 187,491 | 168,511 | 153,812 | 124,269 | 95,813 |
Operating Income | -142,911 | -138,431 | -11,988 | 115,014 | 474,220 |
Interest Expense | -7,880 | -3,685 | -1,398 | -2,461 | -3,427 |
Interest & Investment Income | 11,078 | 6,978 | 13,555 | 4,854 | 1,517 |
Currency Exchange Gain (Loss) | -9,200 | 3,137 | 13,325 | 16,506 | -1,662 |
Other Non Operating Income (Expenses) | 14,604 | 4,474 | -18,722 | -28,620 | -434.77 |
EBT Excluding Unusual Items | -134,309 | -127,527 | -5,228 | 105,293 | 470,212 |
Gain (Loss) on Sale of Investments | 19,110 | 24,162 | 13,777 | 36,875 | 892.14 |
Gain (Loss) on Sale of Assets | 13,835 | 14,259 | -68.06 | -434.6 | 23.62 |
Asset Writedown | -1.41 | -1.41 | -1,154 | - | - |
Pretax Income | -101,365 | -89,107 | 7,327 | 141,733 | 471,128 |
Income Tax Expense | -55,525 | -38,990 | -14,990 | 19,281 | 115,989 |
Earnings From Continuing Operations | -45,841 | -50,117 | 22,318 | 122,452 | 355,139 |
Minority Interest in Earnings | -6,855 | -3,764 | - | - | - |
Net Income | -52,696 | -53,881 | 22,318 | 122,452 | 355,139 |
Net Income to Common | -52,696 | -53,881 | 22,318 | 122,452 | 355,139 |
Net Income Growth | - | - | -81.77% | -65.52% | - |
Shares Outstanding (Basic) | 78 | 77 | 77 | 77 | 73 |
Shares Outstanding (Diluted) | 78 | 77 | 77 | 77 | 74 |
Shares Change (YoY) | 1.35% | 0.24% | -0.01% | 4.32% | - |
EPS (Basic) | -675.88 | -697.93 | 290.65 | 1596.18 | 4844.07 |
EPS (Diluted) | -676.46 | -698.00 | 290.00 | 1590.00 | 4810.00 |
EPS Growth | - | - | -81.76% | -66.94% | - |
Free Cash Flow | -185,935 | -292,433 | -14,114 | -197,951 | 493,686 |
Free Cash Flow Per Share | -2384.82 | -3787.93 | -183.27 | -2570.08 | 6686.61 |
Gross Margin | 8.33% | 11.24% | 38.38% | 52.39% | 61.36% |
Operating Margin | -26.72% | -51.74% | -3.24% | 25.18% | 51.05% |
Profit Margin | -9.85% | -20.14% | 6.04% | 26.81% | 38.23% |
Free Cash Flow Margin | -34.76% | -109.30% | -3.82% | -43.34% | 53.14% |
EBITDA | -69,196 | -89,206 | 22,777 | 142,250 | 492,995 |
EBITDA Margin | -12.94% | -33.34% | 6.16% | 31.15% | 53.07% |
D&A For EBITDA | 73,715 | 49,225 | 34,765 | 27,236 | 18,775 |
EBIT | -142,911 | -138,431 | -11,988 | 115,014 | 474,220 |
EBIT Margin | -26.72% | -51.74% | -3.24% | 25.18% | 51.05% |
Effective Tax Rate | - | - | - | 13.60% | 24.62% |
Advertising Expenses | - | 2,296 | 1,849 | 1,190 | 1,909 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.